Evicenter
P&T meetings

Ulixacaltamide

Essential tremor

Regulatory submission
NDA submitted by February 2026
Launch
Not announced
Last updated
78 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Peripheral nerve stimulation

1 evidence topic · 1 source

Randomized trial of transcutaneous peripheral nerve stimulation
OutcomeActive stimulationSham stimulation
Randomized participants“83”“42”
mADL reduction at 90 days“6.9 points”“2.7 points”
Skin irritation“28 of 83 participants (33.7%)”“2 of 42 (4.8%)”